{'fraction_non_alphanumeric': 0.02237926972909305, 'fraction_numerical': 0.008244994110718492, 'mean_word_length': 5.25, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Should all patients receive statins to reduce cancer risk after heart transplantation?

The study by Frolich et al1 in this issue of Circulation adds to the body of evidence that statins as a class of drugs have effects that reduce the chance of cancer initiation and progression, recapitulating findings showing reductions in cancer-related mortality in statin users in other major malignancies such as breast and prostate cancer.2,3 The authors are explicit in recognizing the flaws inherent in interpreting the data from their single-center case series, but nonetheless, the size of their series is substantial, patients have been followed carefully for long and clinically relevant time periods, and the reduction in cancer incidence, from 34% to 13%, is impressive. Furthermore, there is an overall reduction in the cancer-related death rate, …